×
Palvella Therapeutics EBIT 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Palvella Therapeutics ebit from 2014 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Palvella Therapeutics EBIT 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Palvella Therapeutics ebit from 2014 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$141.5B
Gilead Sciences (GILD)
$117.7B
Bristol Myers Squibb (BMY)
$117.6B
Vertex Pharmaceuticals (VRTX)
$105.8B
CSL (CSLLY)
$85.8B
Regeneron Pharmaceuticals (REGN)
$78.8B
GSK (GSK)
$70.7B
Argenex SE (ARGX)
$38.2B
Alnylam Pharmaceuticals (ALNY)
$31.3B
BioNTech SE (BNTX)
$27.3B
Biogen (BIIB)
$21.8B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$18B
Moderna (MRNA)
$15.6B
Genmab (GMAB)
$13.6B
Incyte (INCY)
$13.4B
BioMarin Pharmaceutical (BMRN)
$12.8B
Insmed (INSM)
$12.6B
Sarepta Therapeutics (SRPT)
$11.8B
Bio-Techne Corp (TECH)
$11.6B
Vaxcyte (PCVX)
$10.7B
Exact Sciences (EXAS)
$10.6B
QIAGEN (QGEN)
$10.3B
Swedish Orphan Biovitrum (BIOVF)
$9.8B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$9.1B
Roivant Sciences (ROIV)
$8.7B
Ascendis Pharma (ASND)
$8.5B
Repligen (RGEN)
$8.2B